COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 open label sequential dose escalation and cohort expansion study
evaluating the safety, tolerability and preliminary antitumor activity of COM701 in
combination with BMS-986207 and nivolumab in patients with advanced solid tumors.